ORLEANS, Ontario, Aug. 14, 2018 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that they have concluded a Development and Commercialization agreement with Genacol Canada Corporation. Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation. Genacol will be responsible for the promotion and sales of these products throughout their network in Canada. According to industry statistics the market for topical pain relief products exceeded $2.5 billion. The companies plan to launch the products in 2019.
Tetra Bio-Pharma will use its formulation and regulatory expertise and clinical trial data from its topical cannabinoid and encapsulated cannabis oil (PPP005) trials to create innovative products for Genacol. Tetra Bio-Pharma will work with regulatory to bring these products to markets within Genacol’s sales network. “We are thrilled to partner with Genacol, a market leader in Canada with a sales network in over 40 countries, these products will command a great deal of exposure,” says Dr. Guy Chamberland, interim CEO and Chief Scientific Officer of Tetra Bio-Pharma. “Tetra is in the business of developing cannabinoid derived prescription and natural health products and this agreement will enable Tetra Bio-Pharma to expand the number of offerings to our patients.”
“We are extremely excited about the potential of this partnership we have created with Tetra Bio-Pharma, a world leader in developing cannabinoid derived prescription and natural health products,” stated Martin Vidal, President & Chief Executive Office for Genacol Corporation. “Our research team at Genacol are great believers in the therapeutic properties of cannabinoids. These products that Tetra Bio-Pharma is developing and Genacol will promote and commercialize are expected to play an important role in the pain and inflammation market in Canada. We estimate that these products will generate several millions of dollars in sales for Genacol in Canada.”
A bout Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Genacol Corporation
Genacol Corporation Canada is a leader in the development and marketing of natural health products primarily related to the treatment of joint pain and the maintenance of joint health. Its mission is to improve the quality of life of its customers by offering them a range of innovative natural products. Building on its success in Canada, Genacol has also developed in recent years an international presence with Genacol brand products available in more than 40 countries, including Latin America, Europe, Asia, the Middle East, Africa and the United States. In addition, the Genacol trademark is registered in 81 countries worldwide. The success of Genacol is based on its collagen manufactured using a proprietary process called “AminoLock® Sequential Technology”, which is an ingredient in many of Genacol’s products.
For more information visit: www.genacol.ca/en/about-us/
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
Photos accompanying this announcement are available at
Source: Tetra Bio-Pharma Inc